Contact This Organization

Limbix Health, Inc

Limbix is developing a pipeline of prescription digital therapeutics (PDTs) for adolescent mental health disorders. We are passionate about creating evidence-based digital programs to increase young people’s access to clinically effective mental health treatment. Our first product, SparkRx, is a CBT-based digital therapeutic to treat symptoms of depression in teens and young adults.
To give all young people access to affordable, effective mental health care by giving providers immediate, safe, and evidenced based treatment options they can prescribe to their patients
Type of Organization
Startup - Newly established businesses, investable
Size of Organization
Organization Mailing Address

548 Market St
PMB 91609
San Francisco, CA 94104
United States

SparkRx is a digital therapeutic that provides evidence-based digital intervention for adolescents aged 13-22 with symptoms of depression. It provides clinicians with an immediate, safe and discreet adjunct treatment option they can offer their patients, overcoming common barriers to accessing mental health care.
Category of Innovation
Digital Health - A digital health solution is a technology-based solution whose user is caring for or providing care for themselves (think of a personal app) or another individual (such as a doctor using a tool to help their patient)
Intended End User
Patient - Individuals who receive health care
Provider - Individuals or organizations responsible for providing care to patients (e.g. doctors, nurses, hospital/clinic administrators, etc.)
Impactful Innovation Stage (Click Here for Details)
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
Adolescent depression has increased 50% since COVID and suicide is the #2 cause of death in teens, yet effective care is limited by long waitlists and large out-of-pocket costs for therapy, limited pharmacological options, and stigma surrounding mental health.
Idea/solution to the problem, if applicable
SparkRx was designed to address the barriers to accessing mental health treatment by offering a self-guided, immediate, and clinically validated adjunct treatment option. It can be used as a valuable resource for patients on increasingly long waitlists for therapy, or for those looking for an adjunct to antidepressants medications.

Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
Limbix has partnered with a number of hospital systems including Boston Children’s via the Mass Challenge HealthTech Accelerator and Children’s Hospital Los Angeles via the KidsX Accelerator to further validate our product. We are in the process of working with a top 5 national health plan and an integrated health system to get SparkRx in the hands of hundreds of patients with symptoms of depression.Our team was also awarded a Small Business Innovation (SBIR) grant from the National Institutes of Health to evaluate the feasibility, safety, and efficacy of SparkRx.
Impact (i.e. measurable outcomes), if applicable
In randomized controlled trials, participants who received SparkRx showed a clinically meaningful reduction in depression symptoms (>5 reduction PHQ-8). Participants that consistently engaged with treatment saw a statistically significant reduction in depression symptoms compared to control.
Funding Stage
Series A
List of Funding Sources (if applicable)
Sequoia Capital, GSR Ventures, Storm Ventures, Bixink, JAZZ Venture Partners, Maverick Capital, Digital Garage and Innovation Global
Has your company attested to any codes of conduct?